IMMX shares exploded two weeks ago and have maintained their higher pricing level. Why?

Good day everyone,

Immix Biopharma, Inc. (NASDAQ: IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases.

Current price $5.84/share (as of market close 1-14-22)

We wanted to report on IMMX because it’s a new IPO in the biopharma sector and we want to explore their potential. The company announced that its shares began trading on the NASDAQ on December 16th and the IPO closed on December 20th with an offering of 4,200,000 shares of its common stock at a price of $5.00 per share, for gross proceeds of $21M.

The IPO is less that a month old and like often happens, the company shares declined over the first couple weeks to under $3.50/share. On January 3rd the company announced its lead product candidate, IMX-110 was granted Rare Pediatric Disease (RPD) designation by the Food and Drug Administration for the treatment of pediatric cancer.

IMMX shares more than doubled on the news, closed that day at $5.78/share and have remained near that price range since. A quick check of the IMMX stock chart will show the narrow range the shares have traded in for the past two weeks. Will the company value stay in this narrow range? I think not, I believe it’s going higher and what I say below is why.

Firstly, IMMX has a tiny share structure (7.5M outstanding and only 1.29M in the float) and insiders own 44.6% of the outstanding shares. Altium Capital Management is already in for an 8.27% stake. Competition for IMMX shares is intensifying.

As you read about the IMMX platform below, keep in mind that as of this writing, the company market value is less that $50M and compare that to other companies you know of with promising oncology treatments in development.

The second reason interest is growing in IMMX shares is their novel technology. IMMX is developing a new class of Tissue-Specific Therapeutics, or TSTx, which they believe will replace first-line therapies across a multitude of oncology indications.

That press release on January 3rd opened investor’s eyes to the IMMX cancer treatment technology. It’s new, novel, and quite amazing. As in

My runtime WaffleLink is going through rewrite from mostly dynamic runtime to mostly static runtime and I decided to rewrite its GC and entire heap. For new GC algo I've chooses Immix as there is not much runtimes that use it. Current implementation is 99% complete as it supports conservative root scanning (precise on heap), opporunistic evacuation from fragmented immix blocks. It succesfully passes gcbench(constructing various binary trees) benchmark. Implementation is here: WaffleLink/heap (immix.rs,immix directory). Implementation was based on librcimmixcons but it is different enough from it in both performance and implementation i.e bitmap for marking lines is now allocated inside block memory and bitmap for marking objects is allocated separately from block header as a large chunk of memory based on size of Immix heap. A lot of code needs to be cleaned up but it works just fine right now! More optimizations on GC soon :D

There was already post in this subreddit that there is another implementation of "exotic" GC algorithm inside runtime, but now I released it as library that can be linked with your apps, vms etc and used almost like BDWGC except you have to define object layout properly using GCRTTI type. It is not much docummented but it should be pretty easy to use. (example.c,examples/simple.rs). And yes this library supports heap defragmentation!

Any feedback is appreciated, if anyone will find issue,bug or have suggestions you can either write it here or create issue in repository.

Source: libimmixcons

Hi to all! I have runtime in Rust called WaffleLink and recently I decided to redesign it to be more static and in future self-host it like JikesRVM did. When I started work on memory management there was one question: what GC algorithm to use? I've thought that lazy generational mark and sweep is a good option and it worked really well but it had performance close to using reference counting so I decided: why not write conservative on stack,preicse on heap moving GC? Solution for this problem found easily and it was Immix collector. It is simple to implement,allows for conservative roots on stack(no additional API is needed to track roots on stack) and it is possible to opportunistically move objects there when heap is fragmented.

This GC is not available as a crate but it is possible to release crate for it if someone will ask for it. :)

Performance

This collector absolutely beats std::rc::Rc with mimalloc,jemalloc and glibc malloc on all POSIX systems in gcbench benchmark which constructs binary trees: gcbench.rs.

Benchmark results for gcbench on iMac mid 2011 is here: benchmark results

Advantages over Rc, rust-gc and other crates

• This collector has zero overhead at mutator time. It does not use reference counting to track roots (it is possible to do this if you really need it using Rooted<T>): you just allocate pointer and it can easily find it on stack and it can even sometimes identify GC object in references from Gc<T> type.
• Gc<T> is copy which allows for easily passing it everywhere without cloning it.
• Moving collection when heap is fragmented. It helps a lot since it evacuates objects from fragmented blocks and puts them to empty one which speedups allocation after evacation cycle.

Limitations

• There is no finalization at the moment so GC does not invoke destructors if there is any
• It is not recommended to have pointers to other heap objects like Box or std::vec::Vec inside GC object.
• You have to reimplement std types that allocate on heap i.e Vec and HashMap so they will allocate inside GC heap, so far I have Array,GcVec and HashMap types implemented inside src/runtime

Hi. PL dilettante here. Note that I know very little about GC implementation so please correct any misconceptions.

I've been poking around various GC methods and stumbled upon a talk describing the JVM G1 generational mark-region collector, which eventually led me to the Immix (summarized in this nice blog post) mark-region GC. It seems to have fantastic results compared to mark-sweep, mark-compact, and semi-space collectors, essentially combining the best aspects of all three (Scala/Native seems to agree). However, there aren't many mainstream languages that are considering supporting it (that I know of).

Is Immix really revolutionary in the sense that it can compete with the above GCs in their own specialties (space, pause-time...)? Has it been difficult to parallelize? Would Immix be a better general-purpose GC for imperative (Java, C++?) or functional languages (specifically Haskell)? Would it be beneficial to combine it with generational collection à la G1? Which other GC algorithm might better deserve my blind idealism?

EDIT: Fixed link to blog post.

Yeah so this kind of Simms it up. I looked further into it and couldn’t find anything else stating that and I don’t feel like it fits but maybe? Do any of you know anything about this?

I just found out there was a GSoC project on implementing an Immix collector for GHC.

While the numbers on that Wiki page look promising, I'm surprised this hasn't gained more traction at the time. I wonder why the prototype was never finished? Well, probably due to time constraints, as always. Were there any problems that meant it could never be faster than the status quo?

Also I see that /u/simonmar's paper on a parallel GC variant seemed to implement its own Immix scheme.

I'm probably most interested in a short chronolical breakdown of the decision process (if there was any) that prevented the Immix collector from being truly integrated, because I couldn't find any ticket (this doesn't count) or similar resources on this.

Updated DD 01-20-22 9:30AM EST

ImmixBio (IMMX) Announces Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles For IMX-110

Good morning everyone,

Immix Biopharma, Inc. (NASDAQ: IMMX) Updated Coverage

Current price $5.71/share (as of 10:20 am EST 1-19-22)

IMMX looks to have back filled the pre-market gap up from $6.65/share. Now consolidating, could we see another afternoon run as we did yesterday? I think it's a good possibility.

This morning IMMX announced interim safety data for their monotherapy Phase 1b/2a clinical trial of their lead product MX-110 for treatment of soft tissue sarcoma. The data indicated 100% completion of IMX-110 planned treatment cycles. Completion of planned treatment cycles refers to lack of drug-related interruptions (cycle delays, dose reductions, or dose interruptions due to drug toxicity).

https://preview.redd.it/xkl1nxkmsuc81.png?width=300&format=png&auto=webp&s=937759455ddd11c62cf1bba8bc1a84eb2063455b

The chart above compares IMX-110 with two FDA approved treatments for soft tissue sarcoma (we have included a brief discussion about soft tissue sarcoma below). Yondelis (PharmaMar) had 2020 revenues of $82M and Votrient (Novartis) had 2020 revenues of $653M. Clearly IMX-110 has superior results in their current stage of clinical trials.

IMX-110 and the IMMX SMARxT Platform seem to have the potential to develop into the SOC for soft tissue sarcoma given the fact that all study data thus far has shown superiority over competing compounds.

It is worthy to note that CEO, Dr. Ilya Rachman and CMO, Dr. Graham Ross both have experience at big pharma companies, not only in drug development, but in clinical trials where they have developed strong relationships in the clinical research industry.

The FDA has approved orphan drug designation for IMX-110 for the treatment of soft tissue sarcoma. The FDA has already approved rare pediatric disease designation to IMX-110 for the treatment of a life-threatening pediatric cancer in children, rhabdomyosarcoma.

Why IMMX will emerge as a leading biopharma stock:

New IPO, less than one month and still under the radar. Tiny float of 1.29M shares FDA Orphan Drug Designation FDA Rare Pediatric Disease Designation Novel oncology platform 15 patents and patents pending

Soft Tissue Sarcoma – Mayo Clinic Soft tissue sarcoma is a rare type of cancer that begins in the tissues that connect, support, and surround other body structures. T

IMMIX Biopharma (IMMX) Looks Like it has Plenty of Room to Grow its Value

Good day everyone,

Immix Biopharma, Inc. (NASDAQ: IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases.

Current price $5.65/share (as of 10:00 am. EST 1-18-22)

After closing at $5.84/share in the Friday session, IMMX shares opened lower today at $5.55. The market indices are struggling this morning and we hope that will turn around. In the first 30 minutes of trading IMMX share are above the open but lag the prior sessions close.

IMMX is not the only development/clinical stage company with a novel platform for cancer treatment. I looked at a few of the others and came to two conclusions and maybe you will agree:

I think the IMMX SMARxT Platform has more potential.

IMMX has a lot of room to grow its value.

C4 Therapeutics (CCCC) MV $1.33B

Adaptimmune Therapeutics (ADAP) MV $515M

Immix Biopharma (IMMX) MV $44M

Biolata (BCAB) MV $465M

Upcoming event

An IMMX Investors Day Event, will be held on February 1, 2022, and the launch of an online Q&A platform for all shareholders to submit questions in advance. IMMX shareholders can submit and upload questions to be answered at the event. To submit questions, please visit https://immixbio.com/QA. The Q&A platform will remain open until 5:00pm ET on Thursday, January 20. The live webcast will be available on the Investor Relations website at https://immixbio.com/IR. Following the event, a replay of the event, as well as a transcript, will be available on the same website.

To me, hosting a Q&A session so soon after their IPO indicates a high level of confidence.

Stay tuned for my full report on IMMX coming tomorrow morning.

original report below

____________________

IMMX shares exploded two weeks ago and have maintained their higher pricing level. Why?

Good day everyone,

Immix Biopharma, Inc. (NASDAQ: IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases.

Current price $5.84/share (as of market close 1-14-22)

We wanted to report on IMMX because it’s a new IPO in the biopharma sector and we want to explore their potential. [The company announced](https://finance.yahoo.com/news/immix-biop

IMMX shares exploded two weeks ago and have maintained their higher pricing level. Why?

Good day everyone,

Immix Biopharma, Inc. (NASDAQ: IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases.

Current price $5.84/share (as of market close 1-14-22)

We wanted to report on IMMX because it’s a new IPO in the biopharma sector and we want to explore their potential. The company announced that its shares began trading on the NASDAQ on December 16th and the IPO closed on December 20th with an offering of 4,200,000 shares of its common stock at a price of $5.00 per share, for gross proceeds of $21M.

The IPO is less that a month old and like often happens, the company shares declined over the first couple weeks to under $3.50/share. On January 3rd the company announced its lead product candidate, IMX-110 was granted Rare Pediatric Disease (RPD) designation by the Food and Drug Administration for the treatment of pediatric cancer.

IMMX shares more than doubled on the news, closed that day at $5.78/share and have remained near that price range since. A quick check of the IMMX stock chart will show the narrow range the shares have traded in for the past two weeks. Will the company value stay in this narrow range? I think not, I believe it’s going higher and what I say below is why.

Firstly, IMMX has a tiny share structure (7.5M outstanding and only 1.29M in the float) and insiders own 44.6% of the outstanding shares. Altium Capital Management is already in for an 8.27% stake. Competition for IMMX shares is intensifying.

As you read about the IMMX platform below, keep in mind that as of this writing, the company market value is less that $50M and compare that to other companies you know of with promising oncology treatments in development.

The second reason interest is growing in IMMX shares is their novel technology. IMMX is developing a new class of Tissue-Specific Therapeutics, or TSTx, which they believe will replace first-line therapies across a multitude of oncology indications.

That press release on January 3rd opened investor’s eyes to the IMMX cancer treatment technology. It’s new, novel, and quite amazing. As in